EQS logo

Equasens Société anonyme Stock Price

ENXTPA:EQS Community·€614.8m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 24 Fair Values set on narratives written by author

EQS Share Price Performance

€40.25
-11.45 (-22.15%)
€40.25
-11.45 (-22.15%)
Price €40.25

EQS Community Narratives

There are no narratives available yet.

Recent EQS News & Updates

Equasens Société anonyme (EPA:EQS) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Oct 03
Equasens Société anonyme (EPA:EQS) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Equasens Société anonyme (EPA:EQS) Will Want To Turn Around Its Return Trends

Aug 06
Equasens Société anonyme (EPA:EQS) Will Want To Turn Around Its Return Trends

Investors Appear Satisfied With Equasens Société anonyme's (EPA:EQS) Prospects As Shares Rocket 33%

May 30
Investors Appear Satisfied With Equasens Société anonyme's (EPA:EQS) Prospects As Shares Rocket 33%

Equasens Société anonyme's (EPA:EQS) Dividend Will Be €1.25

May 19
Equasens Société anonyme's (EPA:EQS) Dividend Will Be €1.25

Equasens Société anonyme Key Details

€224.7m

Revenue

€160.8m

Cost of Revenue

€64.0m

Gross Profit

€27.7m

Other Expenses

€36.3m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
Earnings per share (EPS)
2.42
Gross Margin
28.46%
Net Profit Margin
16.15%
Debt/Equity Ratio
16.1%

Equasens Société anonyme Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Flawless balance sheet, undervalued and pays a dividend.

0 Risks
4 Rewards

About EQS

Founded
1996
Employees
1416
CEO
Denis Supplisson
WebsiteView website
equasens.com

Equasens Société anonyme provides healthcare IT solutions in Europe. The company develops electronic equipment, digital and robotic health, and equipment lease financing solutions. It also offers id., a pharmacy management software suite; id. PATIENT for the exchange of healthcare data; id. VENTE, which facilitates and secures prescription sales; id. COMMANDE, which manages orders and inventory; dispensing robots; Ségur id. services; FARMACLICK, a communication protocol; DIFARM, a modular solution for wholesalers-distributors; and PHARE, a retail management tool. In addition, the company offers patient medication adherence, patient loyalty, point-of-sale commercial performance, piloting pharmacy operations, pharmacy team training, securing pharmacy operations and health data, and digital communication solutions; and in-home nursing services and hospital-at-home, hospitals, and telemedicine solutions. Further, it provides id. DESK, an informative and interactive dashboard; id. UP!, a smartphone app; id. EASYQ, a queuing management solution; Miaterapia, a patient app; and MediStory for tracking patient records; ExpressVitale module; and MEDILINK, a health data hosting provider. Additionally, the company offers KAP&LINK2, a terminal with smart card and NFC reader; eS-KAP-Ad, a mobile device with a pre-loaded software; KAP-INSIDE, a mobile terminal; TI-KAP, which allows access to contact and contactless cards; AUTHENTIFICATEUR, a patented patient authentication system; KAP'TEUR by KAPELSE, a patented universal sensor; and NOVIAcare, which analyzes the behavior and activity of the elderly. It serves nursing homes, hospitals, in-house nursing care and hospital-at-home programs, regional health professional communities, multidisciplinary group practices, and individual healthcare professionals. The company was incorporated in 1996 and is headquartered in Villers-les-Nancy, France. Equasens Société anonyme is a subsidiary of Marque Verte Sante.

Market Insight

Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading

French Market Performance

  • 7 Days: 1.6%
  • 3 Months: 1.3%
  • 1 Year: 5.2%
  • Year to Date: 7.3%
The market is up 1.6% over the last week, with the Consumer Discretionary sector leading the way, up 6.5%. In the last year, the market has climbed 5.2%. Looking forward, earnings are forecast to grow by 12% annually. Market details ›